Showing 491-500 of 3494 results for "".
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap
- Iron Oxides in Tinted Sunscreens May Improve Hyperpigmentation Protection: Studyhttps://practicaldermatology.com/news/iron-oxides-in-tinted-sunscreens-may-improve-hyperpigmentation-protection-study/2487035/A literature review and product analysis published in the Journal of Drugs in Dermatology highlighted growing evidence supporting the use of iron oxides in tinted sunscreens for managing hyperpigmentation, while also identif
- Rapid Weight Loss Brings Expanding Soft Tissue Concerns to Dermatologyhttps://practicaldermatology.com/news/rapid-weight-loss-brings-expanding-soft-tissue-concerns-to-dermatology/2486936/A new analysis suggests rapid weight loss from GLP-1 agents, bariatric surgery, or lifestyle change is associated with measurable declines in skin elasticity and soft tissue volume.Rapid and intentional weight loss (driven by bariatric surgery, glucagon-l
- FDA Flags Six Additional Gel Nail Removers for Banned Chemicalhttps://practicaldermatology.com/news/fda-flags-six-additional-gel-nail-removers-for-banned-chemical/2486820/The US Food and Drug Administration (FDA) has identified six additional cosmetic products marketed as gel nail polish removers that contain methylene chloride, a substance prohibited for use in cosmetics, according to a statement from the agency.</
- CKD Linked to Higher Complication Risk After Mohs Surgeryhttps://practicaldermatology.com/news/ckd-linked-to-higher-complication-risk-after-mohs-surgery/2486676/Chronic kidney disease (CKD) was associated with increased postoperative complications following Mohs micrographic surgery (MMS), according to results of a study published as a Research Letter in the Journal of Drugs in Dermatology Authors evaluated
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://practicaldermatology.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat